{"id":"05511","slug":"mats-proteomics-test--05511","source":{"id":"05511","dataset":"techtransfer","title":"MATS Proteomics Test","description_":"<p>Because abnormal protein expression is associated with many human diseases, biomarker discovery is fundamental to diagnostic innovation. Clinical and research labs need a new state-of-the-art analytical technology for protein detection and quantitation at the whole proteome level. Current biochemical and immuno-assays have many limitations and are expensive to perform in high volumes. Moreover, the high volume of biomarkers identified in the discovery phase means that only a small fraction are able to be validated and subsequently translated into clinical tests.</p><p><h2>Description</h2>MATS Proteomics Technology was developed to accurately measure the absolute amounts of thousands of proteins in a complex biological sample. This novel hybrid technology combines mass spectrometry techniques and machine learning to perform absolute protein quantitation in plasma, urine, or tissue samples at the proteome level. Our MATS Proteomics Technology is a game changer in the field of clinical diagnostics for personalized patient care and will revolutionize a medical testing market in which more than one billion tests are performed per year just in the United States.</p><p><h2>Applications</h2>· Measure the differential expression levels of thousands of proteins in human plasma, urine, and other biofluids, tissue, or FFPE samples\r<br>· Identify and validate diagnostic biomarkers and drug targets\r<br>· Serve as a new generation clinical test that iterative enhances the sensitivity and specificity of the testing algorithms as more and more samples are analyzed\r<br>· Treating cancer, depression, and kidney diseases\r<br>· Revolutionizing personalized patient care</p><p><h2>Advantages</h2>· Enables a new generation of clinical tests with built-in biomarker discovery research component\r<br>· Allows instant and iterative validation of biomarker using machine learning-based prediction models.</p><p></p><p><h2>IP Status</h2>Copyright</p><p></p>","tags":[],"file_number":"05511","collections":[],"meta_description":"Hybrid mass-spectrometry + ML platform enabling absolute, high-throughput proteome quantitation for biomarker discovery and clinical diagnostics.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":4.0,\"timeliness\":3.0},\"weighted_score\":3.6,\"risks\":[\"Age >3 years (dated 2020) may reduce novelty/competitive urgency\",\"Potential IP/IP status unclear (Copyright)\",\"Regulatory/clinical translation hurdles for proteomics in diagnostics\",\"Need for demonstrated clinical utility in diverse cohorts\"],\"one_sentence_take\":\"Strong novelty and scalability potential with ML-enhanced MS proteomics, but dated reference and uncertain readiness for near-term deployment limit overall impact.\"}","lead_inventor_name":"Kunhong Xiao","lead_inventor_dept":"Med-Pharmacology and Chemical Biology","technology_type":"Diagnostic/Assay","technology_subtype":"Biomarker","therapeutic_areas":[],"therapeutic_indications":[],"custom_tags":[],"all_tech_innovators":["Fei Fang","Kunhong Xiao"],"date_submitted":"2020-09-24"},"highlight":{},"matched_queries":null,"score":0.0}